Cargando…

Serum vascular endothelial growth factor b and metabolic syndrome incidence in the population based cohort Di@bet.es study

BACKGROUND/OBJECTIVES: Although vascular endothelial growth factor b (VEGFb) might have an impact on the development of obesity, diabetes and related disorders, the possible relationship between VEGFb serum levels and the incidence of these metabolic complications in humans is still unknown. The aim...

Descripción completa

Detalles Bibliográficos
Autores principales: Lago-Sampedro, Ana, Lhamyani, Said, Valdés, Sergio, Colomo, Natalia, Maldonado-Araque, Cristina, González-Molero, Inmaculada, Doulatram-Gamgaram, Viyey, Delgado, Elias, Chaves, Felipe J., Castaño, Luis, Calle-Pascual, Alfonso, Franch-Nadal, Josep, Rojo-Martínez, Gemma, García-Serrano, Sara, García-Escobar, Eva
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9584818/
https://www.ncbi.nlm.nih.gov/pubmed/35987953
http://dx.doi.org/10.1038/s41366-022-01212-1
_version_ 1784813357486833664
author Lago-Sampedro, Ana
Lhamyani, Said
Valdés, Sergio
Colomo, Natalia
Maldonado-Araque, Cristina
González-Molero, Inmaculada
Doulatram-Gamgaram, Viyey
Delgado, Elias
Chaves, Felipe J.
Castaño, Luis
Calle-Pascual, Alfonso
Franch-Nadal, Josep
Rojo-Martínez, Gemma
García-Serrano, Sara
García-Escobar, Eva
author_facet Lago-Sampedro, Ana
Lhamyani, Said
Valdés, Sergio
Colomo, Natalia
Maldonado-Araque, Cristina
González-Molero, Inmaculada
Doulatram-Gamgaram, Viyey
Delgado, Elias
Chaves, Felipe J.
Castaño, Luis
Calle-Pascual, Alfonso
Franch-Nadal, Josep
Rojo-Martínez, Gemma
García-Serrano, Sara
García-Escobar, Eva
author_sort Lago-Sampedro, Ana
collection PubMed
description BACKGROUND/OBJECTIVES: Although vascular endothelial growth factor b (VEGFb) might have an impact on the development of obesity, diabetes and related disorders, the possible relationship between VEGFb serum levels and the incidence of these metabolic complications in humans is still unknown. The aim of our study was to evaluate the association between VEGFb serum levels and the new-onset of metabolic syndrome (MS) and its components in the Spanish adult population after 7.5 years of follow-up. SUBJECTS/METHODS: A total of 908 subjects from the Di@bet.es cohort study without MS at cross-sectional stage according to International Diabetes Federation (IDF) or Adult Treatment Panel III (ATP-III) criteria were included. Additionally, five sub-populations were grouped according to the absence of each MS component at baseline. Socio-demographic, anthropometric and clinical data were recorded. The Short Form of International Physical Activity Questionnaire (SF-IPAQ) was used to estimate physical activity. A fasting blood extraction and an oral glucose tolerance test were performed. Serum determinations of glucose, lipids, hsCRP and insulin were made. VEGFb levels were determined and categorized according to the 75th percentile of the variable. New cases of MS and its components were defined according to ATPIII and IDF criteria. RESULTS: A total of 181 or 146 people developed MS defined by IDF or ATP-III criteria respectively. Serum triglyceride levels, hs-CRP and systolic blood pressure at the baseline study were significantly different according to the VEGFb categories. Adjusted logistic regression analysis showed that the likelihood of developing MS and abdominal obesity was statistically reduced in subjects included in the higher VEGFb category. CONCLUSION: Low serum levels of VEGFb may be considered as early indicators of incident MS and abdominal obesity in the Spanish adult population free of MS, independently of other important predictor variables.
format Online
Article
Text
id pubmed-9584818
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-95848182022-10-22 Serum vascular endothelial growth factor b and metabolic syndrome incidence in the population based cohort Di@bet.es study Lago-Sampedro, Ana Lhamyani, Said Valdés, Sergio Colomo, Natalia Maldonado-Araque, Cristina González-Molero, Inmaculada Doulatram-Gamgaram, Viyey Delgado, Elias Chaves, Felipe J. Castaño, Luis Calle-Pascual, Alfonso Franch-Nadal, Josep Rojo-Martínez, Gemma García-Serrano, Sara García-Escobar, Eva Int J Obes (Lond) Article BACKGROUND/OBJECTIVES: Although vascular endothelial growth factor b (VEGFb) might have an impact on the development of obesity, diabetes and related disorders, the possible relationship between VEGFb serum levels and the incidence of these metabolic complications in humans is still unknown. The aim of our study was to evaluate the association between VEGFb serum levels and the new-onset of metabolic syndrome (MS) and its components in the Spanish adult population after 7.5 years of follow-up. SUBJECTS/METHODS: A total of 908 subjects from the Di@bet.es cohort study without MS at cross-sectional stage according to International Diabetes Federation (IDF) or Adult Treatment Panel III (ATP-III) criteria were included. Additionally, five sub-populations were grouped according to the absence of each MS component at baseline. Socio-demographic, anthropometric and clinical data were recorded. The Short Form of International Physical Activity Questionnaire (SF-IPAQ) was used to estimate physical activity. A fasting blood extraction and an oral glucose tolerance test were performed. Serum determinations of glucose, lipids, hsCRP and insulin were made. VEGFb levels were determined and categorized according to the 75th percentile of the variable. New cases of MS and its components were defined according to ATPIII and IDF criteria. RESULTS: A total of 181 or 146 people developed MS defined by IDF or ATP-III criteria respectively. Serum triglyceride levels, hs-CRP and systolic blood pressure at the baseline study were significantly different according to the VEGFb categories. Adjusted logistic regression analysis showed that the likelihood of developing MS and abdominal obesity was statistically reduced in subjects included in the higher VEGFb category. CONCLUSION: Low serum levels of VEGFb may be considered as early indicators of incident MS and abdominal obesity in the Spanish adult population free of MS, independently of other important predictor variables. Nature Publishing Group UK 2022-08-20 2022 /pmc/articles/PMC9584818/ /pubmed/35987953 http://dx.doi.org/10.1038/s41366-022-01212-1 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Lago-Sampedro, Ana
Lhamyani, Said
Valdés, Sergio
Colomo, Natalia
Maldonado-Araque, Cristina
González-Molero, Inmaculada
Doulatram-Gamgaram, Viyey
Delgado, Elias
Chaves, Felipe J.
Castaño, Luis
Calle-Pascual, Alfonso
Franch-Nadal, Josep
Rojo-Martínez, Gemma
García-Serrano, Sara
García-Escobar, Eva
Serum vascular endothelial growth factor b and metabolic syndrome incidence in the population based cohort Di@bet.es study
title Serum vascular endothelial growth factor b and metabolic syndrome incidence in the population based cohort Di@bet.es study
title_full Serum vascular endothelial growth factor b and metabolic syndrome incidence in the population based cohort Di@bet.es study
title_fullStr Serum vascular endothelial growth factor b and metabolic syndrome incidence in the population based cohort Di@bet.es study
title_full_unstemmed Serum vascular endothelial growth factor b and metabolic syndrome incidence in the population based cohort Di@bet.es study
title_short Serum vascular endothelial growth factor b and metabolic syndrome incidence in the population based cohort Di@bet.es study
title_sort serum vascular endothelial growth factor b and metabolic syndrome incidence in the population based cohort di@bet.es study
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9584818/
https://www.ncbi.nlm.nih.gov/pubmed/35987953
http://dx.doi.org/10.1038/s41366-022-01212-1
work_keys_str_mv AT lagosampedroana serumvascularendothelialgrowthfactorbandmetabolicsyndromeincidenceinthepopulationbasedcohortdibetesstudy
AT lhamyanisaid serumvascularendothelialgrowthfactorbandmetabolicsyndromeincidenceinthepopulationbasedcohortdibetesstudy
AT valdessergio serumvascularendothelialgrowthfactorbandmetabolicsyndromeincidenceinthepopulationbasedcohortdibetesstudy
AT colomonatalia serumvascularendothelialgrowthfactorbandmetabolicsyndromeincidenceinthepopulationbasedcohortdibetesstudy
AT maldonadoaraquecristina serumvascularendothelialgrowthfactorbandmetabolicsyndromeincidenceinthepopulationbasedcohortdibetesstudy
AT gonzalezmoleroinmaculada serumvascularendothelialgrowthfactorbandmetabolicsyndromeincidenceinthepopulationbasedcohortdibetesstudy
AT doulatramgamgaramviyey serumvascularendothelialgrowthfactorbandmetabolicsyndromeincidenceinthepopulationbasedcohortdibetesstudy
AT delgadoelias serumvascularendothelialgrowthfactorbandmetabolicsyndromeincidenceinthepopulationbasedcohortdibetesstudy
AT chavesfelipej serumvascularendothelialgrowthfactorbandmetabolicsyndromeincidenceinthepopulationbasedcohortdibetesstudy
AT castanoluis serumvascularendothelialgrowthfactorbandmetabolicsyndromeincidenceinthepopulationbasedcohortdibetesstudy
AT callepascualalfonso serumvascularendothelialgrowthfactorbandmetabolicsyndromeincidenceinthepopulationbasedcohortdibetesstudy
AT franchnadaljosep serumvascularendothelialgrowthfactorbandmetabolicsyndromeincidenceinthepopulationbasedcohortdibetesstudy
AT rojomartinezgemma serumvascularendothelialgrowthfactorbandmetabolicsyndromeincidenceinthepopulationbasedcohortdibetesstudy
AT garciaserranosara serumvascularendothelialgrowthfactorbandmetabolicsyndromeincidenceinthepopulationbasedcohortdibetesstudy
AT garciaescobareva serumvascularendothelialgrowthfactorbandmetabolicsyndromeincidenceinthepopulationbasedcohortdibetesstudy